Cosmos Holdings Inc. Common Stock

Day range

$0.22 – $0.27

Open

$0.26

Prev close

$0.26

Volume

1.87M

Market cap

$26.27M

Shares out

100.63M

P/E

—

P/S

0.35

P/B

1.27

P/FCF

—

ROE

-118.0%

ROA

-39.7%

Debt/Equity

0.78

Div yield

0.00%

As of Oct 23, 2026

• Business updateOct 22, 2026

  On October 20, 2026, the Company issued its Chief Executive Officer's letter to shareholders providing a 2026 business update.

• Preliminary resultsOct 9, 2026

  On October 7, 2026, Cosmos Health Inc. (the "Company") issued a press release announcing its preliminary revenue for the nine months ended September 30, 2026 (the "Press Release").

• Share repurchase programAug 20, 2026

  Press Release dated August 19, 2026, entitled "Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway."

• Annual meeting resultsJul 16, 2026

  On July 15, 2026, the Company held its 2026 Annual Meeting. Of the 60,043,491 shares of common stock of the Company outstanding on the record date, 28,315,417 shares were present at the Annual Meeting in person or by proxy, representing approximately 47% of the total outstanding shares eligible to vote. All proposals passed, and the directors recommended by the Company were elected.

• Share repurchase programJul 6, 2026

  the Board of Directors (the "Board") of Cosmos Health Inc. (the "Company") authorized and approved a share repurchase program for up to $5 million of the currently outstanding shares of the Company's common stock over a period of 6 months, ending on December 31, 2026, unless extended by the Company.

Days to cover

1.0

Short interest

2.56M

Avg volume

5.05M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
  positiveBenzinga· Jun 11, 2026
• Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility
  positiveGlobeNewswire Inc.· Oct 10, 2025
• Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units
  positiveGlobeNewswire Inc.· Oct 3, 2025
• Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
  positiveGlobeNewswire Inc.· Sep 22, 2025
• Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
  positiveGlobeNewswire Inc.· Sep 11, 2025